Search Results - "Aggarwal, Sanjay K."

ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease by Jagasia, Madan, Lazaryan, Aleksandr, Bachier, Carlos R, Salhotra, Amandeep, Weisdorf, Daniel J, Zoghi, Behyar, Essell, James, Green, Laurie, Schueller, Olivier, Patel, Jeegar, Zanin-Zhorov, Alexandra, Weiss, Jonathan M, Yang, Zhongming, Eiznhamer, David, Aggarwal, Sanjay K, Blazar, Bruce R, Lee, Stephanie J

“…The rho-associated coiled-coil-containing protein kinase-2 (ROCK2) signaling pathway regulates the Th17/regulatory T cells balance and controls profibrotic…”
Get full text

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study by Cutler, Corey, Lee, Stephanie J., Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Lazaryan, Aleksandr, Ramakrishnan, Aravind, DeFilipp, Zachariah, Salhotra, Amandeep, Chai-Ho, Wanxing, Mehta, Rohtesh, Wang, Trent, Arora, Mukta, Pusic, Iskra, Saad, Ayman, Shah, Nirav N., Abhyankar, Sunil, Bachier, Carlos, Galvin, John, Im, Annie, Langston, Amelia, Liesveld, Jane, Juckett, Mark, Logan, Aaron, Schachter, Levanto, Alavi, Asif, Howard, Dianna, Waksal, Harlan W., Ryan, John, Eiznhamer, David, Aggarwal, Sanjay K., Ieyoub, Jonathan, Schueller, Olivier, Green, Laurie, Yang, Zhongming, Krenz, Heidi, Jagasia, Madan, Blazar, Bruce R., Pavletic, Steven

“…Belumosudil, an investigational oral selective inhibitor of Rho-associated coiled-coil–containing protein kinase 2 (ROCK2), reduces type 17 and follicular T…”
Get full text

Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis by Bachier, Carlos R., Aggarwal, Sanjay K., Hennegan, Kalin, Milgroom, Andrew, Francis, Kevin, Dehipawala, Sumudu, Rotta, Marcello

“…•Chronic graft-versus-host disease (cGVHD) is a common complication of hematopoietic cell transplantation.•cGVHD is an area of unmet need, as shown by…”
Get full text

Genome-Wide Association Study for Type 2 Diabetes in Indians Identifies a New Susceptibility Locus at 2q21 by TABASSUM, Rubina, CHAUHAN, Ganesh, CHIDAMBARAM, Manickam, SHARMA, Amitabh, CHAVALI, Sreenivas, SENGUPTA, Shantanu, RAMAKRISHNAN, Lakshmi, VENKATESH, Pradeep, AGGARWAL, Sanjay K, GHOSH, Saurabh, PRABHAKARAN, Dorairaj, SRINATH, Reddy K, OM PRAKASH DWIVEDI, SAXENA, Madhukar, BANERJEE, Monisha, MATHUR, Sandeep, BHANSALI, Anil, SHAH, Viral N, SRI VENKATA MADHU, MARWAHA, Raman K, BASU, Analabha, SCARIA, Vinod, MCCARTHY, Mark I, MAHAJAN, Anubha, VENKATESAN, Radha, MOHAN, Viswanathan, TANDON, Nikhil, BHARADWAJ, Dwaipayan, JAISWAL, Alok, KAUR, Ismeet, BANDESH, Khushdeep, SINGH, Tejbir, BENAN JOHN MATHAI, PANDEY, Yogesh

“…Indians undergoing socioeconomic and lifestyle transitions will be maximally affected by epidemic of type 2 diabetes (T2D). We conducted a two-stage…”
Get full text

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213) by Cutler, Corey, Lee, Stephanie J., Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Ramakrishnan, Aravind, Eiznhamer, David, Schueller, Olivier, Yang, Zhongming, Green, Laurie S., Aggarwal, Sanjay K., Blazar, Bruce R., Pavletic, Steven Z., Jagasia, Madan

“…▪ Introduction: Belumosudil (KD025) is a novel oral selective rho-associated coiled-coil kinase 2 (ROCK2) inhibitor specifically designed for the treatment of…”
Get full text

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective by Jakubowiak, Andrzej J, Campioni, Marco, Benedict, Ágnes, Houisse, Ivan, Tichy, Eszter, Giannopoulou, Andromachi, Aggarwal, Sanjay K, Barber, Beth L, Panjabi, Sumeet

“…To assess the economic value of carfilzomib (Kyprolis), this study developed the Kyprolis Global Economic Model (K-GEM), which examined from a United States…”
Get more information

Venous thromboembolism prophylaxis in medical ICU patients in Asia (VOICE Asia): A multicenter, observational, cross-sectional study by Parikh, Kamal C, Oh, Doyeun, Sittipunt, Chanchai, Kalim, Harmani, Ullah, Saleem, Aggarwal, Sanjay K

“…Abstract Objectives The VOICE Asia study aimed to establish the mode of thromboprophylaxis in medical patients admitted to intensive care units (ICU), and to…”
Get full text

Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in Asian patients with diabetes: The Registry for Assessing OAD Usage in Diabetes Management (REASON) Asia study (在亚洲糖尿病患者中评估基线特征、血糖控制情况以及口服降糖药物使用情况：使用登记表评估糖尿病治疗中口服药使用情况（REASON）的亚洲研究) by Vichayanrat, Apichati, Matawaran, Bien J., Wibudi, Aris, Ferdous, Hossain S., Aamir, Azizul Hasan, Aggarwal, Sanjay K., Bajpai, Shailendra

“…Background To assess baseline characteristics, glycemic control, and treatment with oral antidiabetic drugs (OAD) in type 2 diabetes mellitus (T2DM) patients…”
Get full text

Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex by Lei, S Z, Pan, Z H, Aggarwal, S K, Chen, H S, Hartman, J, Sucher, N J, Lipton, S A

“…Nitric oxide (NO) is an important messenger both systemically and in the CNS. In digital Ca2+ imaging and patch-clamp experiments, clinically available nitroso…”
Get more information

Severe GI Toxicities Remain a Significant Source of Clinical Meaningful Morbidity Especially in Older Patients Receiving Autologous Transplant for Lymphoma by Shouse, Geoffrey, Frank, Annabel Kate, Aggarwal, Sanjay K., Kavalerchik, Edward, Frazer, John K, Finnegan, Paul, Fakhri, Bita

“…Introduction: High-dose chemotherapy and autologous hematopoietic cell transplant (HDT-AHCT) is considered a standard-of-care (SOC) consolidation therapy for…”
Get full text

Epidemiology and Real-World Treatment of Chronic Graft-Versus-Host Disease Post Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis by Bachier, Carlos R., Aggarwal, Sanjay K., Hennegan, Kalin, Milgroom, Andrew, Francis, Kevin, Rotta, Marcello

“…Background Chronic Graft-Versus-Host Disease (cGVHD) is a complication of hematopoietic cell transplantation (HCT). While the clinical outcomes of cGVHD are…”
Get full text

Results of a Phase 1 Open Label Dose Escalation Trial of AB-205 (Allogeneic Engineered Endothelial Cell Therapy) in Adults with Lymphoma Undergoing High-Dose Therapy and Autologous Hematopoietic Cell Transplantation (HDT-AHCT) by Scordo, Michael, Budde, Lihua E, Abedi, Mehrdad, Mulroney, Carolyn, Fakhri, Bita, Pawarode, Attaphol, Dholaria, Bhagirathbhai, Kavalerchik, Edward, Aggarwal, Sanjay K., Qazilbash, Muzaffar H., Finnegan, Paul, Giralt, Sergio A.

“…Introduction: HDT-AHCT is a standard and potentially curative therapy for patients with high risk, chemosensitive lymphomas. Improvements in supportive care…”
Get full text

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) - Long-Term Follow-up of a Phase 2a Study (KD025-208) by Jagasia, Madan, Salhotra, Amandeep, Bachier, Carlos R., Zoghi, MD, PhD, FACP, Behyar, Lazaryan, Aleksandr, Weisdorf, Daniel J., Essell, James, Green, Laurie S., Schueller, Olivier, Huang, Lindy, Yang, Zhongming, Eiznhamer, David, Aggarwal, Sanjay K., Blazar, Bruce R., Lee, Stephanie J.

“…Introduction: cGVHD exhibits both autoimmune and fibrotic features across multiple organ systems. KD025 is an orally available Rho-associated coiled-coil…”
Get full text

Once-Weekly Carfilzomib with Dexamethasone Demonstrated Promising Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma Regardless of Age and Prior Bortezomib Exposure by Berdeja, Jesus G., Rifkin, Robert M., Lyons, Roger, Yang, Hui, Zahlten-Kuemeli, Anita, Aggarwal, Sanjay K., Iskander, Karim, Berenson, James

“…Background: The multicenter phase 1/2 CHAMPION-1 study (NCT01677858) showed that once-weekly carfilzomib and dexamethasone was well tolerated and active in…”
Get full text

Cardiac Events in Real-World Multiple Myeloma Patients Treated with Carfilzomib: A Retrospective Claims Database Analysis by Chari, Ajai, Aggarwal, Sanjay K., Mezzi, Khalid, Wang, Kenneth, Kim, Christopher, Zhu, Shao, Braunlin, Megan, Werther, Winifred, Mikhael, Joseph

“…Introduction: Multiple myeloma (MM) is a hematologic cancer that mostly affects elderly patients who are at increased risk for development of cardiac-related…”
Get full text

KD025-208: A Phase 2a Study of KD025 for Patients with Chronic Graft Versus Host Disease (cGVHD) — Pharmacodynamics and Updated Results by Jagasia, Madan, Salhotra, Amandeep, Bachier, Carlos R., Essell, James, Weisdorf, Daniel J., Zoghi, Behyar, Green, Laurie S., Schueller, Olivier, Zanin-Zhorov, Alexandra, Weiss, Jonathan M., Eiznhamer, David, Aggarwal, Sanjay K., Blazar, Bruce R., Lee, Stephanie J.

“…Introduction: cGVHD remains a leading cause of post-transplant morbidity / mortality, exhibiting features of both autoimmune and fibrotic diseases across…”
Get full text

Demographic and Comorbidity Characteristics of Newly Diagnosed Multiple Myeloma Patients in the United States: A Real World Data Analysis by Chen, Yaozhu J, De, Ajita P, Cong, Ze, Aggarwal, Sanjay K, Wade, Rolin L

“…Background Multiple myeloma (MM) remains an incurable plasma cell neoplasm with >20,000 new cases diagnosed annually in the United States (US). The…”
Get full text

Belumosudil for Chronic Graft-Versus-Host Disease (cGVHD) after 2 or More Prior Lines of Therapy: The Rockstar Study (KD025-213) by Cutler, Corey, Lee, Stephanie J, Arai, Sally, Rotta, Marcello, Zoghi, Behyar, Ramakrishnan, Aravind, Lazaryan, Aleksandr, Eiznhamer, David A, Schueller, Olivier, Yang, Zhongming, Green, Laurie S., Aggarwal, Sanjay K, Blazar, Bruce R., Pavletic, Steven Z., Jagasia, Madan

Get full text

Assessment of baseline characteristics, glycemic control and oral antidiabetic treatment in A sian patients with diabetes: The R egistry for A ssessing OAD U sage in D iabetes M anagement ( REASON ) A sia study (在亚洲糖尿病患者中评估基线特征、血糖控制情况以及口服降糖药物使用情况：使用登记表评估糖尿病治疗中口服药使用情况（REASON）的亚洲研究) by Vichayanrat, Apichati, Matawaran, Bien J., Wibudi, Aris, Ferdous, Hossain S., Aamir, Azizul Hasan, Aggarwal, Sanjay K., Bajpai, Shailendra

“…Abstract Background To assess baseline characteristics, glycemic control, and treatment with oral antidiabetic drugs ( OAD ) in type 2 diabetes mellitus ( T2DM…”
Get full text

KD025 for Patients with Chronic Graft-Versus-Host Disease (cGVHD) – Long-Term Follow-up of a Phase 2a Study (KD025-208) by Weisdorf, Daniel J., Jagasia, Madan, Salhotra, Amandeep, Bachier, Carlos R., Zoghi, Behyar, Lazaryan, Aleksandr, Essell, James H., Green, Laurie S., Schueller, Olivier, Yang, Zhongming, Eiznhamer, David A., Aggarwal, Sanjay K., Blazar, Bruce R., Lee, Stephanie

“…cGVHD exhibits both autoimmune and fibrotic features across multiple organ systems. KD025 is an orally available Rho-associated coiled-coil kinase 2 (ROCK2)…”
Get full text